ORAMED PHARMACEUTICALS INC.
ORMPUS売上高
$2M
百万USD
営業利益
$-15M
百万USD
純利益
$64M
百万USD
ROE
32.1%
最新FY
EPS
$1.50
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $1M | $-6M | - |
| FY2021 | Q2 | $1M | $-5M | - |
| FY2021 | Q3 | $1M | $-5M | - |
| FY2021 | FY | $3M | $-23M | - |
| FY2022 | Q1 | $1M | $-11M | - |
| FY2022 | Q2 | $1M | $-11M | $0.27 |
| FY2022 | Q3 | $1M | - | $0.18 |
| FY2022 | FY | $3M | - | $0.94 |
| FY2023 | Q1 | $1M | - | $0.07 |
| FY2023 | Q2 | $1M | $-1M | $0.03 |
| FY2023 | Q3 | $1M | $-3M | $0.08 |
| FY2023 | FY | $1M | $6M | $0.14 |
| FY2024 | Q1 | $1M | $2M | $0.04 |
| FY2024 | Q2 | $1M | $9M | $0.22 |
| FY2024 | Q3 | - | $-20M | $-0.48 |
| FY2024 | FY | $1M | $-19M | $-0.48 |
| FY2025 | Q1 | $2M | $-8M | $-0.19 |
| FY2025 | Q2 | - | $13M | $0.31 |
| FY2025 | Q3 | - | $48M | $1.13 |
| FY2025 | FY | $2M | $64M | $1.50 |
| FY2026 | Q1 | $2M | $38M | $0.91 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | $1M | $2M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M |
| 営業利益 | $-10M | $-11M | $-14M | $-15M | $-12M | $-24M | $-41M | $-16M | $-13M | $-15M |
| 純利益 | $-11M | $-10M | $-13M | $-14M | $-12M | $-23M | - | $6M | $-19M | $64M |
| 総資産 | $43M | $39M | $47M | $35M | $45M | $128M | $162M | $221M | $155M | $231M |
| 純資産 | - | - | - | - | - | $117M | $151M | $163M | $145M | $200M |
| 自己資本 | $26M | $19M | $31M | $19M | $33M | $116M | $152M | $164M | $146M | $200M |
| 営業CF | $5M | $-6M | $-15M | $-13M | $-12M | $-21M | $-28M | $-10M | $-8M | $-9M |
| EPS | - | - | - | - | - | - | $0.94 | $0.14 | $-0.48 | $1.50 |
| BPS | $1.97 | $1.34 | $1.79 | $1.11 | $1.39 | $3.04 | $3.82 | $4.04 | $3.58 | $4.94 |
| ROE | -41.9% | -54.5% | -40.9% | -74.0% | -35.0% | -19.9% | - | 3.4% | -13.1% | 32.1% |